{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T18:34:55Z","timestamp":1789929295918,"version":"4.0.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,8]],"date-time":"2015-09-08T00:00:00Z","timestamp":1441670400000},"content-version":"vor","delay-in-days":464,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","valueinhealthjournal.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.jval.2014.02.008","type":"journal-article","created":{"date-parts":[[2014,5,10]],"date-time":"2014-05-10T16:15:16Z","timestamp":1399738516000},"page":"310-319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Cost-Effectiveness of Second-Generation Antipsychotics for the Treatment of Schizophrenia"],"prefix":"10.1016","volume":"17","author":[{"given":"Taehwan","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen M.","family":"Kuntz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2014.02.008_bib1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/archpsyc.1993.01820140007001","article-title":"The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services","volume":"50","author":"Regier","year":"1993","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jval.2014.02.008_bib2","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.4088\/JCP.v66n0906","article-title":"The economic burden of schizophrenia in the United States in 2002","volume":"66","author":"Wu","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jval.2014.02.008_bib3","doi-asserted-by":"crossref","first-page":"920","DOI":"10.4088\/JCP.v63n1010","article-title":"Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database","volume":"63","author":"Gianfrancesco","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jval.2014.02.008_bib4","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1176\/appi.ajp.161.9.1709","article-title":"Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications","volume":"161","author":"Leslie","year":"2004","journal-title":"Am J Psychiatry"},{"issue":"1, Suppl.","key":"10.1016\/j.jval.2014.02.008_bib5","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jval.2014.02.008_bib6","unstructured":"American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia second edition. Available from: http:\/\/psychiatryonline.org\/guidelines.aspx. [Accessed October 6, 2013]."},{"key":"10.1016\/j.jval.2014.02.008_bib7","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2014.02.008_bib8","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1176\/ajp.2006.163.12.2080","article-title":"Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia","volume":"163","author":"Rosenheck","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jval.2014.02.008_bib9","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1001\/jama.290.20.2693","article-title":"Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial","volume":"290","author":"Rosenheck","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2014.02.008_bib10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1192\/bjp.bp.106.028654","article-title":"Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy","volume":"191","author":"Davies","year":"2007","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jval.2014.02.008_bib11","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0188-4409(02)00409-5","article-title":"A cost-effectiveness clinical decision analysis model for treatment of schizophrenia","volume":"33","author":"Palmer","year":"2002","journal-title":"Arch Med Res"},{"key":"10.1016\/j.jval.2014.02.008_bib12","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2753.2006.00782.x","article-title":"Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia","volume":"13","author":"Bounthavong","year":"2007","journal-title":"J Eval Clin Pract"},{"key":"10.1016\/j.jval.2014.02.008_bib13","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1524-4733.2004.75008.x","article-title":"Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model","volume":"7","author":"Vera-Llonch","year":"2004","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2014.02.008_bib14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1478-7547-7-4","article-title":"Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States","volume":"7","author":"Furiak","year":"2009","journal-title":"Cost Eff Resour Alloc"},{"key":"10.1016\/j.jval.2014.02.008_bib15","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1365-2753.2009.01189.x","article-title":"Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis","volume":"16","author":"McIntyre","year":"2010","journal-title":"J Eval Clin Pract"},{"key":"10.1016\/j.jval.2014.02.008_bib16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1185\/03007995.2010.537594","article-title":"Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia","volume":"27","author":"Ascher-Svanum","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jval.2014.02.008_bib17","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1185\/03007990802507547","article-title":"Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK","volume":"24","author":"Davies","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jval.2014.02.008_bib18","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/01.CIR.0000111245.75752.C6","article-title":"Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute\/American Heart Association conference on scientific issues related to definition","volume":"109","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jval.2014.02.008_bib19","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.schres.2007.12.487","article-title":"Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE schizophrenia trial: prospective data from phase 1","volume":"101","author":"Meyer","year":"2008","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jval.2014.02.008_bib20","doi-asserted-by":"crossref","first-page":"575","DOI":"10.7326\/0003-4819-136-8-200204160-00006","article-title":"Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test?","volume":"136","author":"Stern","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jval.2014.02.008_bib21","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","article-title":"Prediction of coronary heart disease using risk factor categories","volume":"97","author":"Wilson","year":"1998","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.jval.2014.02.008_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006633.pub2","article-title":"Clozapine versus other atypical antipsychotics for schizophrenia","author":"Asenjo Lobos","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jval.2014.02.008_bib23","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.schres.2008.01.028","article-title":"Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review","volume":"101","author":"De Hert","year":"2008","journal-title":"Schizophr Res"},{"issue":"1, Suppl.","key":"10.1016\/j.jval.2014.02.008_bib24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2165\/00019053-200523001-00007","article-title":"Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA","volume":"23","author":"Edwards","year":"2005","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2014.02.008_bib25","unstructured":"Healthcare cost and utilization project. Available from: http:\/\/hcupnet.ahrq.gov\/. [Accessed November 25, 2012]."},{"key":"10.1016\/j.jval.2014.02.008_bib26","unstructured":"Farahati F, Boucher M, Moulton K, et al. Atypical Antipsychotic Monotherapy for Schizophrenia: Clinical Review and Economic Evaluation of First Year of Treatment. Technology Report No. 91. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health, 2007"},{"key":"10.1016\/j.jval.2014.02.008_bib27","doi-asserted-by":"crossref","unstructured":"Hansen KA. Hyperprolactinemia and the dopamine receptor. US Endocrine Disease 2006. Available from: http:\/\/www.touchbriefings.com\/pdf\/1815\/Hansen_edit.pdf. [Accessed October 15, 2012].","DOI":"10.17925\/USE.2006.00.1.74"},{"key":"10.1016\/j.jval.2014.02.008_bib28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1377\/hlthaff.2009.0155","article-title":"The economic burden of diabetes","volume":"29","author":"Dall","year":"2010","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.jval.2014.02.008_bib29","unstructured":"American Heart Association. Heart disease and stroke statistics \u2013 2006 Update. Available from: http:\/\/www.heart.org\/HEARTORG\/. [Accessed November 11, 2012]."},{"key":"10.1016\/j.jval.2014.02.008_bib30","year":"2013"},{"key":"10.1016\/j.jval.2014.02.008_bib31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1477-7525-6-105","article-title":"Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation","volume":"6","author":"Briggs","year":"2008","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jval.2014.02.008_bib32","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.4088\/JCP.7075tx3c","article-title":"Overview of managing medical comorbidities in patients with severe mental illness","volume":"70","author":"McIntyre","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jval.2014.02.008_bib33","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/01.mlr.0000172050.67085.4f","article-title":"A national catalog of preference-based scores for chronic conditions in the United States","volume":"43","author":"Sullivan","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.jval.2014.02.008_bib34","first-page":"1","article-title":"United States life tables, 2008","volume":"61","author":"Arias","year":"2012","journal-title":"Natl Vital Stat Rep"},{"key":"10.1016\/j.jval.2014.02.008_bib35","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1192\/bjp.177.3.212","article-title":"Causes of the excess mortality of schizophrenia","volume":"177","author":"Brown","year":"2000","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jval.2014.02.008_bib36","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.2337\/diacare.28.12.2839","article-title":"Relative risk of mortality associated with diabetes as a function of birth weight","volume":"28","author":"Leibson","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jval.2014.02.008_bib37","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1136\/hrt.2010.198507","article-title":"Effects of depressive symptoms and coronary heart disease and their interactive associations on mortality in middle-aged adults: the Whitehall II cohort study","volume":"96","author":"Nabi","year":"2010","journal-title":"Heart"},{"issue":"Suppl. 3","key":"10.1016\/j.jval.2014.02.008_bib38","first-page":"3","article-title":"Reducing clozapine-related morbidity and mortality: 5 years of experience with the clozaril national registry","volume":"59","author":"Honigfeld","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jval.2014.02.008_bib39","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","article-title":"11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)","volume":"374","author":"Tiihonen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2014.02.008_bib40","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of sudden cardiac death","volume":"360","author":"Ray","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2014.02.008_bib41","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/pds.1424","article-title":"Cardiovascular risks of atypical antipsychotic drug treatment","volume":"16","author":"Drici","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jval.2014.02.008_bib42","unstructured":"National Institute for Health and Care Excellence. Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. Technology Appraisal Guidance 43. London, UK: National Institute for Health and Care Excellence, 2002"},{"key":"10.1016\/j.jval.2014.02.008_bib43","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","article-title":"Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder","volume":"60","author":"Potkin","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jval.2014.02.008_bib44","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.biopsych.2008.07.033","article-title":"A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia","volume":"65","author":"Fleischhacker","year":"2009","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jval.2014.02.008_bib45","doi-asserted-by":"crossref","first-page":"572","DOI":"10.4088\/JCP.08m04421","article-title":"A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia","volume":"70","author":"Kane","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jval.2014.02.008_bib46","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.eurpsy.2007.03.002","article-title":"A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study","volume":"22","author":"Kerwin","year":"2007","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.jval.2014.02.008_bib47","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/YIC.0b013e32816f7779","article-title":"Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study","volume":"22","author":"Zimbroff","year":"2007","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.jval.2014.02.008_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006569.pub4","article-title":"Aripiprazole versus other atypical antipsychotics for schizophrenia","author":"Khanna","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jval.2014.02.008_bib49","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1185\/03007995.2010.542745","article-title":"Cost-effectiveness analysis of aripiprazole vs standard-of-care in the management of community-treated patients with schizophrenia: STAR study","volume":"27","author":"King","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jval.2014.02.008_bib50","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1185\/03007990802490512","article-title":"One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia","volume":"24","author":"Edwards","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jval.2014.02.008_bib51","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.schres.2005.08.010","article-title":"A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls","volume":"80","author":"Goff","year":"2005","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jval.2014.02.008_bib52","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","article-title":"Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III","volume":"80","author":"McEvoy","year":"2005","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jval.2014.02.008_bib53","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/JCP.0b013e318036bfbb","article-title":"Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis","volume":"27","author":"Paton","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jval.2014.02.008_bib54","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1600-0447.2011.01792.x","article-title":"Augmentation of clozapine with a second antipsychotic\u2014a meta-analysis","volume":"125","author":"Taylor","year":"2012","journal-title":"Acta Psychiatr Scand"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301514000424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301514000424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T11:54:34Z","timestamp":1648986874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301514000424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S1098301514000424"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2014.02.008","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Second-Generation Antipsychotics for the Treatment of Schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2014.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}